RiverGlades Family Offices LLC acquired a new position in shares of Pfizer (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 6,820 shares of the biopharmaceutical company’s stock, valued at approximately $247,000.
A number of other institutional investors have also recently bought and sold shares of the business. First Dallas Securities Inc. acquired a new stake in Pfizer in the fourth quarter valued at $118,000. Delphi Private Advisors LLC grew its holdings in Pfizer by 84.3% in the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,600 shares during the last quarter. Americafirst Capital Management LLC acquired a new stake in Pfizer in the third quarter valued at $127,000. Oak Point Wealth Management acquired a new stake in Pfizer in the fourth quarter valued at $165,000. Finally, Cerebellum GP LLC acquired a new stake in Pfizer in the fourth quarter valued at $166,000. 71.65% of the stock is currently owned by institutional investors.
Several analysts have weighed in on PFE shares. Morningstar set a $38.00 target price on Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. Credit Suisse Group set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a report on Friday. Barclays lowered Pfizer from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $41.00 to $38.00 in a report on Thursday, April 5th. UBS set a $42.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a report on Wednesday, January 24th. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $40.08.
NYSE PFE opened at $35.64 on Friday. Pfizer has a twelve month low of $31.67 and a twelve month high of $39.43. The stock has a market cap of $212.40 billion, a P/E ratio of 13.45, a price-to-earnings-growth ratio of 1.77 and a beta of 0.89. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The firm had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the prior year, the business posted $0.69 earnings per share. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. equities analysts anticipate that Pfizer will post 2.95 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, May 10th. This represents a $1.36 annualized dividend and a yield of 3.82%. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.
In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares in the company, valued at $1,374,505.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ian C. Read sold 132,312 shares of the stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total value of $4,764,555.12. The disclosure for this sale can be found here. Insiders have sold 380,349 shares of company stock worth $13,829,340 over the last quarter. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.